Antiestrogen therapy in pancreatic carcinoma: a preliminary report.

Abstract

Ten patients with unresected pancreatic carcinoma, treated with Nolvadex 10 mg 3 times a day were compared to a historic untreated control group. The median survival was 7 months in the treated group compared to 3 months in the untreated. In the control group all patients died within the first 9 months, in the treated group 40% of the patients were still alive after 14 months.